Zolinza (Vorinostat) Patent Expiration, LOE Window & CMS Spending

Zolinza (Vorinostat) by Merck & Co.: FDA Orange Book core substance LOE 2027-03-11 (last listed 2028-03-18), 0 AB generics, $4.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMerck & Co.
FDA Application & PathwayN021991 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2027-03-11
Last Listed Patent or Exclusivity Date2028-03-18
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$4.2M
2024 Medicare Part D Spend$3.7M
2024 Medicaid Spend$509K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.